AMYLOIDOSIS AND INFLAMMATORY BOWEL DISEASE: FACT OR MITH?
- Autori: Sinagra, E.; Ciofalo, M.; Tomasello, G.; Cappello, F.; Morreale, G.; Amvrosiadis, G.; Damiani, P.; Damiani, F.; Pompei, G.; Rizzo, A.; Canale, C.; Mastrocinque, G.; Carini, F.; Raimondo, D.
- Anno di pubblicazione: 2017
- Tipologia: Articolo in rivista (Articolo in rivista)
Inflammatory Bowel Disease (IBD), which includes both Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic idiopathic inflammatory disorder affecting the gastrointestinal tract. Extraintestinal manifestations (EIM) are common in patients with IBD, and occur in 6-47% of patients with CD or UC. EIM can involve organs other than the gastrointestinal tract such as skin, eyes, joints, biliary tract and kidneis. Renal and urinary involvement particularly occurs in 4-23% of patients with IBD. Among the renal complications of IBD, seconfary amyloidosis (AA-type, AAA) is a rare but serious complication. renal amyloidosis has been proven to be the most common lethal manifestation of IBD-associated amyloidosis, since renal involvement rapidly leads to end-stage renal failure. A few studies suggest that AAA is more prevalent in CD than in UC, mainly occurring in male patients with an extensive long-lasting and penetrating ddisease pattern. The therapeutic approaches of IBD-associated AAA are based both on control of the chronic inflammatory process that causes the production and storage of serum amyloid A (SAA), which is a precursor of the amyloid, as well as on destabilizing amyloid fibrils so that they can no longer maintain their pleated sheet configuration; however, in patients with end-stage renal disease, the only therapeutic options still available are hemodyalisis and renal transplantation. Whether effective treatment exists for AAA remain controversial.